YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Coronary artery disease
- Focus Biomarker; Pharmacodynamics
- Acronyms YELLOW-II
- 27 Oct 2016 Results published in the Journal of the American College of Cardiology
- 28 Oct 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 15 Jul 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.